Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 412 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Early-Stage Breast Cancer Clear all
Completed Phase 3 Interventional

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

NCT01479244
View directory record Official record
Conditions
Breast Cancer With Low to Intermediate HER2 Expression
Interventions
NeuVax™ vaccine, Leukine® (sargramostim, GM-CSF) and water for injection
Biological
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
81
States / cities
Bessemer, Alabama • Mobile, Alabama • Peoria, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

NCT01806675
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Hypopharyngeal Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Laryngeal Cancer, Recurrent Lip and Oral Cavity Cancer, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Nasopharyngeal Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Oropharyngeal Cancer, Recurrent Pancreatic Cancer, Recurrent Paranasal Sinus and Nasal Cavity Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Colon Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer, Tongue Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
Drug
Lead sponsor
Sanjiv Sam Gambhir
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Not applicable Interventional Results available

Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer

NCT00615901
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 10, 2026, 2:46 AM EDT
Not listed Not applicable Interventional

Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory

NCT01157130
View directory record Official record
Conditions
Early Stage Breast Cancer (Stage 0-III)
Interventions
Exercise Regimen
Other
Lead sponsor
Nevada Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 10, 2026, 2:46 AM EDT
Not listed Phase 2 Interventional

Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery

NCT00251329
View directory record Official record
Conditions
Breast Cancer
Interventions
neoadjuvant chemotherapy
Drug
Lead sponsor
Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
6
States / cities
Jacksonville, Florida • Lakeland, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2007 · Synced Sep 10, 2026, 2:46 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
Interventions
LOXO-292
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Not listed Not applicable Interventional

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

NCT00436709
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, adjuvant therapy, immunoscintigraphy
Biological · Drug · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Early Phase 1 Interventional

Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer

NCT00527293
View directory record Official record
Conditions
Breast Cancer
Interventions
adjuvant therapy, 3-dimensional conformal radiation therapy, brachytherapy
Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
4
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 10, 2026, 2:46 AM EDT
Recruiting Not applicable Interventional

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

NCT07630402
View directory record Official record
Conditions
Breast Cancer With Low to Intermediate HER2 Expression
Interventions
Echocardiogram
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers

NCT00909662
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults
Interventions
assessment of therapy complications, cognitive assessment, fatigue assessment and management
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Sep 10, 2026, 2:46 AM EDT
Active, not recruiting No phase listed Observational

Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation

NCT04854005
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast surgery
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Hartford, Connecticut • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional

Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

NCT01502592
View directory record Official record
Conditions
Breast Cancer, Invasive Adenocarcinoma of the Breast
Interventions
Cryoablation, Ipilimumab
Procedure · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Sep 10, 2026, 2:46 AM EDT
Terminated No phase listed Observational

Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates

NCT01166581
View directory record Official record
Conditions
Early Stage Breast Cancer
Interventions
Not listed
Lead sponsor
Summa Health System
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Sep 10, 2026, 2:46 AM EDT
Recruiting Not applicable Interventional

A Study of the TheraBionic P1 Device in Breast Cancer

NCT07218432
View directory record Official record
Conditions
Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage IIIA, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer
Interventions
TheraBionic P1 Device
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
22 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Clarkston, Michigan • Detroit, Michigan • Farmington Hills, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Not listed Not applicable Interventional

Immune Effects in Patients Treated With Whole Breast Irradiation

NCT03567044
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood Draw
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
45 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

NCT05112536
View directory record Official record
Conditions
Triple Negative Breast Cancer, Breast Cancer
Interventions
Trilaciclib, Cylophosphamide, Doxorubicin, Paclitaxel, Carboplatin (Investigator discretion), Pembrolizumab (Investigator discretion)
Drug · Biological
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Los Alamitos, California • Santa Monica, California • Whittier, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 10, 2026, 2:46 AM EDT
Not listed Not applicable Interventional

Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)

NCT03025139
View directory record Official record
Conditions
Cancer Survivor, Early-Stage Breast Carcinoma, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Educational Intervention, Laboratory Biomarker Analysis, Meditation Therapy, Questionnaire Administration
Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Up to 49 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Not applicable Interventional Results available

Post Market Study Using the Xoft Axxent System

NCT01017549
View directory record Official record
Conditions
Breast Cancer
Interventions
Electronic brachytherapy (Axxent System)
Radiation
Lead sponsor
Xoft, Inc.
Industry
Eligibility
50 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
10
States / cities
San Mateo, California • Marietta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

Trastuzumab in Treating Older Women With Early-Stage Breast Cancer

NCT00796978
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment
Biological · Other · Procedure
Lead sponsor
Cynthia Owusu, MD
Other
Eligibility
60 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
11
States / cities
Miami, Florida • Winston-Salem, North Carolina • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 10, 2026, 2:46 AM EDT
Completed No phase listed Observational

Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer

NCT05945290
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma, Locally Advanced Breast Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Results available

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

NCT04081389
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Celecoxib, Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Paclitaxel, Recombinant Interferon Alfa-2b, Rintatolimod
Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 10, 2026, 2:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

NCT00755313
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions
trastuzumab, aromatase inhibition therapy, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, metabolic assessment, questionnaire administration, study of socioeconomic and demographic variables, cognitive assessment, positron emission tomography, fludeoxyglucose F 18
Biological · Drug · Other + 2 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years to 80 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Results available

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

NCT02950259
View directory record Official record
Conditions
Breast Neoplasm, Breast Neoplasm, Male, Triple Negative Breast Cancer
Interventions
Cyclophosphamide, Indomethacin, Omeprazole, Multivitamin
Drug · Dietary Supplement
Lead sponsor
Providence Health & Services
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 10, 2026, 2:46 AM EDT
Recruiting Not applicable Interventional

Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery

NCT05327608
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
Interventions
Short-Term Fasting, Chemotherapy, Biospecimen Collection, Questionnaire Administration
Other · Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Cherry Hill, New Jersey • Sewell, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 10, 2026, 2:46 AM EDT